Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Receivables (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Change in Receivables data on record, last reported at -$22.2 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 45.5% year-over-year to -$22.2 million; the TTM value through Dec 2025 reached $10.2 million, up 686.09%, while the annual FY2025 figure was $10.2 million, 686.09% up from the prior year.
  • Change in Receivables reached -$22.2 million in Q4 2025 per PTCT's latest filing, down from $6.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $47.8 million in Q1 2025 and bottomed at -$40.8 million in Q4 2024.
  • Average Change in Receivables over 5 years is $5.2 million, with a median of $3.8 million recorded in 2022.
  • The widest YoY moves for Change in Receivables: up 1166.07% in 2021, down 3307.82% in 2021.
  • A 5-year view of Change in Receivables shows it stood at $16.4 million in 2021, then soared by 44.78% to $23.7 million in 2022, then crashed by 135.23% to -$8.3 million in 2023, then crashed by 388.27% to -$40.8 million in 2024, then soared by 45.5% to -$22.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$22.2 million in Q4 2025, $6.5 million in Q3 2025, and -$21.9 million in Q2 2025.